Be sure to signup for the next Virtual Cafe of Dr. GPCR on the 24th of June! This time, the GPCRdb team ( Dr. David Gloriam , Dr. Reserve your spot for free at: https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #GPCR #GPCRs #DrGPCR

Join us for a fantastic introduction to GPCRdb with Dr. David Gloriam and Dr. Albert Kooistra. Register today: https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

Did you register for our next Dr. GPCR Virtual Cafe? Register today! Addgene's Dr. research or you want to share your materials, this is the place to go. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe

Join us for the first virtual cafe talk to hear about the amazing work that Dr. Brian Arey is doing. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

September 2022 "Morphine, the most widely used analgesic, relieves severe pain by activating the μ-opioid receptor (MOR), whereas naloxone, with only slight structural changes compared to morphine, exhibits inhibitory effect, and is used to treat opioid abuse. The mechanism by which the MOR distinguishes between the two is unclear. Molecular dynamics (MD) simulations on a 1-μs time scale and metadynamics-enhanced conformational sampling are used here to determine the different interactions of these two ligands with MOR: morphine adjusted its pose by continuously flipping deeper into the pocket, whereas naloxone failed to penetrate deeper because its allyl group conflicts with several residues of MOR. The endogenous peptide ligand endomorphin-1 (EM-1) underwent almost no significant conformational changes during the MD simulations. To validate these processes, we employed GIRK4S143T, a MOR-activated Gβγ-protein effector, in combination with mutagenesis and electrophysiological recordings. We verified the role of some key residues in the dynamic recognition of naloxone and morphine and identified the key residue I322, which leads to differential recognition of morphine and naloxone while assisting EM-1 in activating MOR. Reducing the side chain size of I322 (MORI322A) transformed naloxone from an inhibitor directly into an agonist of MOR, and I322A also significantly attenuated the potency of MOR on EM-1, confirming that binding deep in the pocket is critical for the agonistic effect of MOR. This finding reveals a dynamic mechanism for the response of MOR to different ligands and provides a basis for the discovery of new ligands for MOR at the atomic level." Read more at the source #DrGPCR #GPCR #IndustryNews

Gmeiner ,  Peter J McCormick ,  Dorothee Weikert ,  Masha Y Niv ,  Moran Shalev-Benami , et al. Dr. GPCR Kicked Off as a Podcast... our mission but also snag fantastic perks like: Dr. Direct line to the Dr. Jude Children's Research Hospital Welcomes Dr.

their study on Frizzleds act as dynamic pharmacological entities Marina Casiraghi, Robert J Lefkowitz, Peter Join our upcoming Dr. GPCR University hands-on workshop with Dr.  We define a developing country based on World Bank Classifications for its 2024 fiscal year. Check our conversation with Dr. Sam Hoare about this hands-on workshop HERE ⬇⬇⬇ Dr. Dr.

This week's highlight includes congrats to: Makaía M Papasergi-Scott, Peter Gmeiner, Brian K Kobilka, Dr. GPCR University Save the date for our upcoming workshop, starting May 9th, 2024, featuring Dr.  Under Dr. Hoare's expert guidance, you will gain invaluable skills in data analysis. Dr. Terry Kenakin's "Applying Pharmacology to Drug Discovery" course at Dr. Dr.

Your scientific thinking built the foundation, but leadership is what scales it. The Invisible Obstacle   👉 Brilliant science. Stalled progress. It’s a pattern we see far too often in early-stage biotech operations and startups. The experiments work. The data looks promising. But decisions lag, the team spins, and investors get nervous. Science isn’t the problem; scientific thinking is. What makes you excel in the lab can quietly sabotage your leadership in the boardroom. 👉 Scientific thinking  rewards depth, rigor, and precision. But in a startup, those same instincts to analyze deeply, minimize error, and delay action until “enough” data is in can kill momentum . 👉 Most founders don’t even realize they’re still running their company like an academic research group. They explain instead of deciding. They analyze instead of acting.   ✅  This post explores how scientific thinking can become a leadership liability and what mindset shifts are needed to evolve from research reflexes to CEO decisions.   ✅  You don’t need to abandon your scientific instincts. But you do need to adapt them if you want your startup to scale .     The 3 Golden Rules of Scientific Thinking — and Why They Break Down in Biotech Operations Leadership   👉 Scientific thinking trains you to be precise, methodical, and skeptical. These instincts are critical in the lab, but they often undermine leadership when blindly applied in a startup . Let’s unpack the three core “rules” most scientific founders unconsciously carry into their companies:   1️⃣ “Only act when the data is solid.” In research, acting on incomplete or shaky data can destroy your credibility. In startups, waiting too long for certainty can destroy your momentum . 👉 Biotech founders often delay critical business moves, hiring, BD outreach, or funding decisions, because the data isn't “mature enough.” But in business, decisions must be made under uncertainty . Clarity doesn’t precede action; it follows it.   2️⃣ “Eliminate error at all costs” Labs are built around error reduction. You control variables. You minimize noise. But startups are inherently noisy. Trying to eliminate all risk leads to overengineering and stagnation . 👉 Instead of shipping early and iterating, many scientific founders keep refining decks, processes, and team structures until they feel bulletproof. But by then, the window of opportunity has often closed.   3️⃣ “Deep analysis leads to better answers” Scientific training favors deep thinking. More analysis = better outcomes. But in leadership, depth without speed equals paralysis . 👉 Startups don’t reward depth alone; they reward direction and decisiveness . Over-analysis becomes a form of avoidance. And while you're analyzing, someone else is executing.   👉 Bottom line:  Scientific thinking is invaluable, but only when it’s reframed for the role you’re actually in. ✅ You’re not optimizing experiments anymore. You’re steering a company.     Startups Play by Different Rules — and Most Scientific Founders Miss That   A research lab is designed for precision. A startup is designed for progress. And that difference changes everything. 👉 Scientific thinking values thoroughness, error reduction, and complete data before action.  But in the startup environment, these instincts can quickly become liabilities. You rarely have perfect data. 👉 You can’t eliminate every variable. And waiting too long often means missing the moment. Startups demand something different: ✅ Clarity of direction even when the picture is incomplete. The ability to decide when no option is risk-free. The discipline to align a team without all the answers. Founders who keep operating like researchers often create internal confusion. They revise instead of committing. They analyze instead of align. They aim for perfect clarity, and in doing so, they delay momentum, erode trust, and weaken execution. ✅ Scientific thinking can make you cautious when your company needs decisiveness. Unless you update the way you lead, your startup will struggle to translate insight into impact.   Leadership isn’t in your lab notebook; it’s in how you decide     How to Know If You're Still Leading Like a Scientist   👉 Leadership isn’t a title. It’s a way of thinking. And if your thinking is still shaped by academic norms, your startup will keep running like a lab, not a company. 👉Scientific thinking is precise. Leadership thinking is directional. The transition between the two isn’t automatic, even for the most capable founders. It requires conscious shifts in how you process uncertainty, how you frame decisions, and how you lead people through ambiguity. Here are three questions to help you check in with yourself: 1️⃣ Do you delay or dilute decisions while waiting for more clarity? Real leadership often means choosing without all the answers. If you find yourself looping decisions or delegating them upward, you might be leaning on scientific habits to avoid risk.   2️⃣ Do you overvalue internal logic over external action? It’s tempting to refine the deck, rework the roadmap, or re-analyze the market. But leadership is outward-facing. It’s about choosing direction, enabling others to move, and owning tradeoffs with imperfect inputs.   3️⃣ Do you explain more than you align? Explaining a model is not the same as rallying a team. When your communication centers on logic and detail instead of clarity and momentum, your team stays in wait mode, and execution stalls.   ✅ The shift from scientist to CEO  is not about abandoning your expertise. It’s about realizing that your value now lies in decisions, not just in depth.     Strategic Takeaway   👉 Scientific thinking will always be your strength, but it must be reshaped to serve your new role. 👉 As a biotech founder, your impact no longer comes from precision alone, but from your ability to lead through uncertainty, prioritize progress over perfection, and turn insight into execution. ✅  Leadership is not the opposite of science. It’s what gives it direction.   Ready to Break Your Bottlenecks?          If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

Welcome back to your weekly GPCR quest! his article Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter Thank you to all participants in Dr. Terry Kenakin's educational initiative this fall!

It's spring break at Dr. Learn more about Live Masterclasses ➤ Partner Webinars Eurofins DiscoverX (Dr. GeneTex (Dr. Alex Ball)  — A reagent gap that holds back the biology. Details coming soon. Next Week in Boston The Dr. GPCR community gathers in person next week. Come find us ➤ About Dr. GPCR Dr. GPCR is the intelligence and community for GPCR scientists.

Alexander Ball and Dr. Chia-Yi Lin, began. A word that admits what it doesn’t know Much of that trust problem, Dr. Dr. Dr. Lin arrived from a different door. Listen to the full conversation with Dr. Ball and Dr. Lin Watch the webinar recording with Dr. Ball

Secure Your Access Now ➤ 🗣️ “Thank you for bringing this (Principles of Pharmacology I) course with Dr I wish Dr. best for the sake of promoting more educational opportunities that are sorely needed in the field” — Dr GPCR University Learner Dr. GPCR Podcast - Surviving Discovery’s Gauntlet Dr. The Dr. GPCR Team Read Full Edition ➤

Join Dr. Evan O'Brien, PhD, Johns Hopkins University Dr. Dr. Terry Kenakin, UNC and Head Instructor at Terry's Corner Dr. As Dr. Why Dr. GPCR Is in This Conversation At Dr.

. -            Dr. Wendy Young’s talk, during session 3 on day 2, was also incredible. . -            Dr. Wednesday was a key day for Maria, as she got to participate in a panel discussion alongside Dr. Shoichet, Dr. Luc Van Hijfte and Dr. Wendy Young. Amanda Dombrowski from Abbvie, Dr. Charles Yeung from Merck and Dr.

In Episode 168 of the Dr. GPCR Podcast, Dr. And that mindset is precisely what makes their new partnership with Dr. GPCR so powerful. ” — Dr. That’s the mission. ” — Dr. Maria Majellaro Now, as official partners of the Dr. Keyword Cloud:   GPCR data platform , fluorescent ligands , assay development , GPCR research community , Dr

Plus, check out the latest Dr. GPCR tools and key moves in the biotech world. Dr. Become a Dr. GPCR Ambassador - Share & refer with Dr. GPCR.   Join the Affiliate Program     Your Shortcut to Dr. The Dr. Best wishes, The Dr. GPCR Team

Dr. Maria Majellaro’s story, shared in Episode 168 of the Dr. ” — Dr. Maria Majellaro Maria didn’t always know she’d end up in a startup. ” — Dr. With the new  Dr. . 👉 Explore Celtarys’ tools and partnership with Dr.

Dr. Dr. Dr. Dr. Dr. Kenakin revealed  the decision workflow for ranking agonists with translational intent.

, we’re spotlighting Celtarys Research, our newest partner, featured in a blog and podcast with CSO Dr After 40+ years and 250 publications, Dr. Dr. Explore Terry's Corner From Chemistry Lab to GPCR Partner – New Podcast with Celtarys Dr. Stay curious, The Dr. GPCR Team

Hello Sweet GPCR Enthusiasts, This week at Dr. GPCR: a new podcast episode with Dr. Ben Clements, a tour of our official Dr. Scroll down for the science, the strategy, and the sweet stuff 🍬 Dr. The official Dr. GPCR Store is live! Best wishes, The Dr. GPCR Team

GPCR Podcast: Leadership, Impact, and GPCR Signaling with Dr. Dr. Yamina’s open letter reflects on how Dr. I wish Dr. No matter where you are in your GPCR journey, Dr.

As a valued Dr. featuring:   A short, focused video A concise written summary with key takeaways Handpicked references by Dr Your Exclusive Premium Member Benefit:   As a thank you for your continued support of the Dr. GPCR Ecosystem, we're giving Dr. Warmest Regards, The Dr. GPCR Team & Terry’s Desk

The Corner comes will live monthly AMA sessions with Dr. Kenakin. GPCR Updates Learn Pharmacology That Drives Discovery  – From Dr. Explore Dr. This blog post breaks down Dr. Stay curious,   The Dr. GPCR Team

Check out GPCR papers featuring Drs. Bryan Roth, Peter Gmeiner, and Thomas P. Sakmar this week. For Dr. GPCR News, please subscribe to our monthly newsletter. Research Associate Lab Manager Vice President, Medical Affairs Associate Scientist - Technology Explore Dr

They inform SAR, rank compounds, and influence which molecules move forward. In this Terry’s Corner lesson, Dr. Hudson 🎧 Catch up on Part 2 with Dr. GPCR Year in Review: Carrying Better Experiments Into 2026 As 2025 closes, the Dr. Beyond access, Premium sustains the nonprofit mission behind Dr.

GPCR Colleagues & Curiosity-Driven Minds, We’re starting with exciting Dr. sharpen your skills with our new on-demand course, Techniques for Effective Lead Optimization with Dr Dr. Catch up on past Dr. Stay curious, The Dr. GPCR Team

Dr. GPCR Podcast: Chemical Probes for GPCR Imaging with Dr. In this episode, Dr. I will keep Dr. GPCR and the offered resources in my work sphere." Donate : https://www.ecosystem.drgpcr.com/donate Dr.

Dr. Dr. Dr. Dr. Dr.

For Dr. In this episode of the Dr. ” — Dr. Maria Majellaro Maria’s career didn’t start with a desire to launch a company. Celtarys Research, now partnering with Dr. ____________ Keyword Cloud:   GPCR drug discovery , GPCR research community , medicinal chemistry , Dr